Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model

Keith S Abayasiriwardana, Michael K Wood, Cecilia M Prêle, Kimberly A Birnie, Bruce W Robinson, Geoffrey J Laurent, Robin J McAnulty, Steven E Mutsaers

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Malignant mesothelioma is an aggressive fibrous tumor, predominantly of the pleura, with a very poor prognosis. Cell-matrix interactions are recognized important determinants of tumor growth and invasiveness but the role of the extracellular matrix in mesothelioma is unknown. Mesothelioma cells synthesize collagen as well as transforming growth factor-beta (TGF-β), a key regulator of collagen production. This study examined the effect of inhibiting collagen production on mesothelioma cell proliferation in vitro and tumor growth in vivo. Collagen production by mesothelioma cells was inhibited by incubating cells in vitro with the proline analogue thiaproline (thiazolidine-4-carboxylic acid) or by oral administration of thiaproline in a murine tumor model. Cell cytotoxicity was measured using neutral red uptake and lactate dehydrogenase assays. Proliferation was measured by tritiated thymidine incorporation, and inflammatory cell influx, proliferation, apoptosis and angiogenesis in tumors examined by immunohistochemical labelling. Tumor size was determined by tumor weight and collagen production was measured by HPLC. Thiaproline at non-toxic doses significantly reduced basal and TGF-β-induced collagen production by over 50% and cell proliferation by over 65%. In vivo thiaproline administration inhibited tumor growth at 10 days, decreasing the median tumor weight by 80%. The mean concentration of collagen was 50% lower in the thiaproline-treated tumors compared with the controls. There were no significant differences in vasculature or inflammatory cell infiltration but apoptosis was increased in thiaproline treated tumors at day 10. In conclusion, these observations strongly support a role for collagen in mesothelioma growth and establish the potential for inhibitors of collagen synthesis in mesothelioma treatment.

Original languageEnglish
Pages (from-to)198-204
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume510
Issue number2
Early online date23 Jan 2019
DOIs
Publication statusPublished - 5 Mar 2019

Fingerprint

Tumors
Collagen
Mesothelioma
Growth
Neoplasms
Cell proliferation
Cell Proliferation
Tumor Burden
Transforming Growth Factor beta
Apoptosis
Neutral Red
Malignant Mesothelioma
Pleura
thiazolidine-4-carboxylic acid
L-Lactate Dehydrogenase
Proline
Cell Communication
Thymidine
Extracellular Matrix
Oral Administration

Cite this

Abayasiriwardana, Keith S ; Wood, Michael K ; Prêle, Cecilia M ; Birnie, Kimberly A ; Robinson, Bruce W ; Laurent, Geoffrey J ; McAnulty, Robin J ; Mutsaers, Steven E. / Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model. In: Biochemical and Biophysical Research Communications. 2019 ; Vol. 510, No. 2. pp. 198-204.
@article{539ce8f8e95c4a918a024d69e590e755,
title = "Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model",
abstract = "Malignant mesothelioma is an aggressive fibrous tumor, predominantly of the pleura, with a very poor prognosis. Cell-matrix interactions are recognized important determinants of tumor growth and invasiveness but the role of the extracellular matrix in mesothelioma is unknown. Mesothelioma cells synthesize collagen as well as transforming growth factor-beta (TGF-β), a key regulator of collagen production. This study examined the effect of inhibiting collagen production on mesothelioma cell proliferation in vitro and tumor growth in vivo. Collagen production by mesothelioma cells was inhibited by incubating cells in vitro with the proline analogue thiaproline (thiazolidine-4-carboxylic acid) or by oral administration of thiaproline in a murine tumor model. Cell cytotoxicity was measured using neutral red uptake and lactate dehydrogenase assays. Proliferation was measured by tritiated thymidine incorporation, and inflammatory cell influx, proliferation, apoptosis and angiogenesis in tumors examined by immunohistochemical labelling. Tumor size was determined by tumor weight and collagen production was measured by HPLC. Thiaproline at non-toxic doses significantly reduced basal and TGF-β-induced collagen production by over 50{\%} and cell proliferation by over 65{\%}. In vivo thiaproline administration inhibited tumor growth at 10 days, decreasing the median tumor weight by 80{\%}. The mean concentration of collagen was 50{\%} lower in the thiaproline-treated tumors compared with the controls. There were no significant differences in vasculature or inflammatory cell infiltration but apoptosis was increased in thiaproline treated tumors at day 10. In conclusion, these observations strongly support a role for collagen in mesothelioma growth and establish the potential for inhibitors of collagen synthesis in mesothelioma treatment.",
author = "Abayasiriwardana, {Keith S} and Wood, {Michael K} and Pr{\^e}le, {Cecilia M} and Birnie, {Kimberly A} and Robinson, {Bruce W} and Laurent, {Geoffrey J} and McAnulty, {Robin J} and Mutsaers, {Steven E}",
year = "2019",
month = "3",
day = "5",
doi = "10.1016/j.bbrc.2019.01.057",
language = "English",
volume = "510",
pages = "198--204",
journal = "Biochemistry Biophysics Research Communications",
issn = "0006-291X",
publisher = "Academic Press",
number = "2",

}

Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model. / Abayasiriwardana, Keith S; Wood, Michael K; Prêle, Cecilia M; Birnie, Kimberly A; Robinson, Bruce W; Laurent, Geoffrey J; McAnulty, Robin J; Mutsaers, Steven E.

In: Biochemical and Biophysical Research Communications, Vol. 510, No. 2, 05.03.2019, p. 198-204.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhibition of collagen production delays malignant mesothelioma tumor growth in a murine model

AU - Abayasiriwardana, Keith S

AU - Wood, Michael K

AU - Prêle, Cecilia M

AU - Birnie, Kimberly A

AU - Robinson, Bruce W

AU - Laurent, Geoffrey J

AU - McAnulty, Robin J

AU - Mutsaers, Steven E

PY - 2019/3/5

Y1 - 2019/3/5

N2 - Malignant mesothelioma is an aggressive fibrous tumor, predominantly of the pleura, with a very poor prognosis. Cell-matrix interactions are recognized important determinants of tumor growth and invasiveness but the role of the extracellular matrix in mesothelioma is unknown. Mesothelioma cells synthesize collagen as well as transforming growth factor-beta (TGF-β), a key regulator of collagen production. This study examined the effect of inhibiting collagen production on mesothelioma cell proliferation in vitro and tumor growth in vivo. Collagen production by mesothelioma cells was inhibited by incubating cells in vitro with the proline analogue thiaproline (thiazolidine-4-carboxylic acid) or by oral administration of thiaproline in a murine tumor model. Cell cytotoxicity was measured using neutral red uptake and lactate dehydrogenase assays. Proliferation was measured by tritiated thymidine incorporation, and inflammatory cell influx, proliferation, apoptosis and angiogenesis in tumors examined by immunohistochemical labelling. Tumor size was determined by tumor weight and collagen production was measured by HPLC. Thiaproline at non-toxic doses significantly reduced basal and TGF-β-induced collagen production by over 50% and cell proliferation by over 65%. In vivo thiaproline administration inhibited tumor growth at 10 days, decreasing the median tumor weight by 80%. The mean concentration of collagen was 50% lower in the thiaproline-treated tumors compared with the controls. There were no significant differences in vasculature or inflammatory cell infiltration but apoptosis was increased in thiaproline treated tumors at day 10. In conclusion, these observations strongly support a role for collagen in mesothelioma growth and establish the potential for inhibitors of collagen synthesis in mesothelioma treatment.

AB - Malignant mesothelioma is an aggressive fibrous tumor, predominantly of the pleura, with a very poor prognosis. Cell-matrix interactions are recognized important determinants of tumor growth and invasiveness but the role of the extracellular matrix in mesothelioma is unknown. Mesothelioma cells synthesize collagen as well as transforming growth factor-beta (TGF-β), a key regulator of collagen production. This study examined the effect of inhibiting collagen production on mesothelioma cell proliferation in vitro and tumor growth in vivo. Collagen production by mesothelioma cells was inhibited by incubating cells in vitro with the proline analogue thiaproline (thiazolidine-4-carboxylic acid) or by oral administration of thiaproline in a murine tumor model. Cell cytotoxicity was measured using neutral red uptake and lactate dehydrogenase assays. Proliferation was measured by tritiated thymidine incorporation, and inflammatory cell influx, proliferation, apoptosis and angiogenesis in tumors examined by immunohistochemical labelling. Tumor size was determined by tumor weight and collagen production was measured by HPLC. Thiaproline at non-toxic doses significantly reduced basal and TGF-β-induced collagen production by over 50% and cell proliferation by over 65%. In vivo thiaproline administration inhibited tumor growth at 10 days, decreasing the median tumor weight by 80%. The mean concentration of collagen was 50% lower in the thiaproline-treated tumors compared with the controls. There were no significant differences in vasculature or inflammatory cell infiltration but apoptosis was increased in thiaproline treated tumors at day 10. In conclusion, these observations strongly support a role for collagen in mesothelioma growth and establish the potential for inhibitors of collagen synthesis in mesothelioma treatment.

U2 - 10.1016/j.bbrc.2019.01.057

DO - 10.1016/j.bbrc.2019.01.057

M3 - Article

VL - 510

SP - 198

EP - 204

JO - Biochemistry Biophysics Research Communications

JF - Biochemistry Biophysics Research Communications

SN - 0006-291X

IS - 2

ER -